Patent intelligence · WO
WO 2019016112
COMPOSÉS DE QUINOLÉINE À SUBSTITUTION EN POSITIONS 1, 2, 3 ET 4 UTILISÉS EN TANT QUE MODULATEURS DE S1P
COMPOSÉS DE QUINOLÉINE À SUBSTITUTION EN POSITIONS 1, 2, 3 ET 4 UTILISÉS EN TANT QUE MODULATEURS DE S1P
Patent details — WO 2019016112
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Jan 24, 2019
- Expiration
- Jan 19, 2039
- Applicant
- ABBVIE DEUTSCHLAND [DE]
- CPC classes
- A61K 31/ 4725 A I, A61P 25/ 28 A I, A61P/2528
Quick answer
WO 2019016112 (COMPOSÉS DE QUINOLÉINE À SUBSTITUTION EN POSITIONS 1, 2, 3 ET 4 UTILISÉS EN TANT QUE MODULATEURS DE S1P) is held by ABBVIE DEUTSCHLAND [DE]. Status: granted. Granted Jan 24, 2019. Expires Jan 19, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ABBVIE DEUTSCHLAND [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 4725 A I, A61P 25/ 28 A I, A61P/2528
More from ABBVIE DEUTSCHLAND [DE]
Related pharmaceutical patents in our USPTO index.
-
WO 2024243450
MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET
granted -
CA 3266054
COMPOSÉS DE N-MÉTHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE
granted -
CA 3259391
POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1
granted -
CA 3245150
COMBINAISONS AVEC UN ANTICORPS ANTI-CD39 HUMAIN, UN ANTICORPS ANTI-PD-1 HUMAIN ET UNE CHIMIOTHÉRAPIE CONTRE LE CANCER GASTRIQUE
granted -
US 2023174645
ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS
granted -
CA 3235096
METHODES DE TRAITEMENT DE L'ANEMIE CAUSEE PAR UNE MALADIE RENALE
granted -
CA 3207179
METHODES DE TRAITEMENT DE LA MALADIE DE CROHN ET DE LA COLITE ULCEREUSE
granted -
US 2022169620
SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS
granted
Frequently asked questions
What is US patent 2019016112?
WO 2019016112 (COMPOSÉS DE QUINOLÉINE À SUBSTITUTION EN POSITIONS 1, 2, 3 ET 4 UTILISÉS EN TANT QUE MODULATEURS DE S1P) is held by ABBVIE DEUTSCHLAND [DE]. Status: granted. Granted Jan 24, 2019. Expires Jan 19, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2019016112?
ABBVIE DEUTSCHLAND [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.
When does WO 2019016112 expire?
Our index shows an expiration date of Jan 19, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.